Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which HIV prevention shot do patients prefer? new study aims to find out

NCT ID NCT07379658

Knowledge-focused Sponsor: Anupama Raghuram MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will survey 128 adults in Louisville, Kentucky who are already taking or starting a long-acting injectable HIV PrEP shot. Participants will answer questionnaires about their satisfaction and adherence to either lenacapavir or cabotegravir over 12 months. The goal is to understand real-world preferences and outcomes, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors and patients choose the long-acting injectable PrEP that works best for them, improving HIV prevention.
What could go wrong
This is an observational study, not a treatment trial. It only measures satisfaction and adherence, not whether the drugs prevent HIV better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants receiving injectable PrEP in Louisville, KY.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 and older 2. Deemed eligible for HIV PrEP per healthcare provider 3. Receiving or initiating LAI PrEP, defined as: 1. Current use of CAB or LEN LAI PrEP at study entry 2. Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment 4. Receiving PrEP services in Louisville, KY 5. Able to provide informed consent and complete study assessments Exclusion Criteria: 1. HIV diagnosis prior to enrollment 2. Currently on oral PrEP with no plans to switch to LAI PrEP 3. Hypersensitivities to LEN or CAB 4. Pregnant or planning to become pregnant 5. PI discretion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV pre-exposure prophylaxis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV pre-exposure prophylaxis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Norton Healthcare

    Louisville, Kentucky, 40202, United States

  • University of Louisville, Kent School of Social Work

    Louisville, Kentucky, 40292, United States

  • University of Louisville, School of Public Health and Information Sciences

    Louisville, Kentucky, 40202, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.